Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther 2010 Aug 15;10(4):391-6
Date
06/25/2010Pubmed ID
20574156Pubmed Central ID
PMC3040854DOI
10.4161/cbt.10.4.12449Scopus ID
2-s2.0-77956408178 (requires institutional sign-in at Scopus site) 43 CitationsAbstract
The current classification of ductal carcinoma in situ (DCIS) is based on nuclear grade, architectural differentiation and the presence of necrosis that does not adequately predict the likelihood of recurrence after breast conserving therapy; therefore, there is a critical need to identify novel predictors of DCIS progression. Ninety seven cases of DCIS were included in the study. CD10 and SPARC expression in tumor stroma was assessed by standard immunoperoxidase method with ani-CD 10 and anti-SPARC antibodies. The staining was scored semi-quantitatively as negative, weak or strong. Statistical analysis was performed using the Fisher's exact test. Multivariable analysis was conducted utilizing Exact Logistic Regression software (SAS 9.1 and LogExact). A significant association was observed between the recurrence status and time to recurrence with expression of CD10 (p < 0.001) and SPARC (p < 0.001). When combining both SPARC and CD10 expression there was a strong correlation with the shortest time to recurrence. Stromal CD10 and SPARC expression are new markers of an increased risk for DCIS recurrence, independent of commonly assessed clinical parameters. Thus, stromal CD10 and SPARC expression levels are promising markers of DCIS recurrence and warrant evaluation in larger prospective studies.
Author List
Witkiewicz AK, Freydin B, Chervoneva I, Potoczek M, Rizzo W, Rui H, Brody JR, Schwartz GF, Lisanti MPMESH terms used to index this publication - Major topics in bold
Biomarkers, TumorBreast Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Female
Humans
Immunoenzyme Techniques
Neoplasm Recurrence, Local
Neoplasm Staging
Neprilysin
Osteonectin
Prognosis
Stromal Cells
